Evidence map›Paper›PMID 27543498›Full record

ReviewBritish medical bulletin2016

Childhood amblyopia: current management and new trends.

Vijay Tailor, Manuela Bossi, John A Greenwood, Annegret Dahlmann-Noor

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British medical bulletin, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 4 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Guideline
  2. Amblyopia: progress and promise of functional magnetic resonance imaging.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Vijay TailorNIHR Biomedical Research Centre at Moorfields Eye Hospital, London, UK UCL Institute of Ophthalmology, London, UK.
Manuela BossiUCL Institute of Ophthalmology, London, UK.
John A GreenwoodExperimental Psychology, University College London, London, UK.
Annegret Dahlmann-NoorNIHR Biomedical Research Centre at Moorfields Eye Hospital, London, UK UCL Institute of Ophthalmology, London, UK annegret.dahlmann-noor@moorfields.nhs.uk.
Moorfields Eye Hospital · GBUniversity College London · GB

Funding

Medical Research Council MR/K024817/1
6 · The paper itself

Abstract

INTRODUCTION OR

backgroundWith a prevalence of 2-5%, amblyopia is the most common vision deficit in children in the UK and the second most common cause of functional low vision in children in low-income countries. SOURCES OF DATA: Pubmed, Cochrane library and clinical trial registries (clinicaltrials.gov, ISRCTN, UKCRN portfolio database). AREAS OF AGREEMENT: Screening and treatment at the age of 4-5 years are cost efficient and clinically effective. Optical treatment (glasses) alone can improve visual acuity, with residual amblyopia treated by part-time occlusion or pharmacological blurring of the better-seeing eye. Treatment after the end of the conventional 'critical period' can improve vision, but in strabismic amblyopia carries a low risk of double vision. AREAS OF CONTROVERSY: It is not clear whether earlier vision screening would be cost efficient and associated with better outcomes. Optimization of treatment by individualized patching regimes or early start of occlusion, and novel binocular treatment approaches may enhance adherence to treatment, provide better outcomes and shorten treatment duration. GROWING POINTS: Binocular treatments for amblyopia. AREAS TIMELY FOR DEVELOPING RESEARCH: Impact of amblyopia on education and quality of life; optimal screening timing and tests; optimal administration of conventional treatments; development of child-friendly, effective and safe binocular treatments.

Indexed as

EyeglassesAmblyopiaChildCost-Benefit AnalysisEarly DiagnosisHumansMass ScreeningPrevalenceQuality of LifeTreatment OutcomeUnited Kingdomamblyopia*/diagnosisamblyopia*/therapychildhumanstreatment outcomevision screeningvisual acuity

Identifiers

PMID27543498
PMCPMC5862311
OpenAlexW2509332759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.